Enviar búsqueda
Cargar
Building on Drug Safety - the new EU guidelines May 2012
•
Descargar como PPT, PDF
•
3 recomendaciones
•
1,439 vistas
Doctors.net.uk
Seguir
Claire Tilstone - MHRA
Leer menos
Leer más
Salud y medicina
Empresariales
Tecnología
Denunciar
Compartir
Denunciar
Compartir
1 de 10
Descargar ahora
Recomendados
Update on new pv legislation plg june2012
Update on new pv legislation plg june2012
danisowich
Who is the EU QPPV and what do they do
Who is the EU QPPV and what do they do
Fiorenza Gaudenzi
Pharmacovigilance evmpd submission
Pharmacovigilance evmpd submission
eCTDconsultancy
EU PV Modules - What are they?
EU PV Modules - What are they?
Vaska Toné
Changes in European PV post July 2011
Changes in European PV post July 2011
Amrutha VC
An Introduction to the Pharmacovigilance System Master File
An Introduction to the Pharmacovigilance System Master File
TransPerfect Trial Interactive
New EU PV regulations
New EU PV regulations
Dr.Vijay Talla
Safety Reports: PBRER / PSUR
Safety Reports: PBRER / PSUR
Azierta
Recomendados
Update on new pv legislation plg june2012
Update on new pv legislation plg june2012
danisowich
Who is the EU QPPV and what do they do
Who is the EU QPPV and what do they do
Fiorenza Gaudenzi
Pharmacovigilance evmpd submission
Pharmacovigilance evmpd submission
eCTDconsultancy
EU PV Modules - What are they?
EU PV Modules - What are they?
Vaska Toné
Changes in European PV post July 2011
Changes in European PV post July 2011
Amrutha VC
An Introduction to the Pharmacovigilance System Master File
An Introduction to the Pharmacovigilance System Master File
TransPerfect Trial Interactive
New EU PV regulations
New EU PV regulations
Dr.Vijay Talla
Safety Reports: PBRER / PSUR
Safety Reports: PBRER / PSUR
Azierta
Presentation: Prescription Medicines Reforms
Presentation: Prescription Medicines Reforms
TGA Australia
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
László Árvai
Periodic Safety Update Reports: Some commonly asked questions
Periodic Safety Update Reports: Some commonly asked questions
TGA Australia
ABPI briefing on the Falsified Medicines Directive (FMD) OCT 2016
ABPI briefing on the Falsified Medicines Directive (FMD) OCT 2016
Association of the British Pharmaceutical Industry (ABPI)
Presentation: The Australian and International landscape - keynote forum
Presentation: The Australian and International landscape - keynote forum
TGA Australia
Presentation: Spotlight on prescription medicine post-market reforms
Presentation: Spotlight on prescription medicine post-market reforms
TGA Australia
ABPI briefing on the Falsified Medicines Directive (FMD) FEB 2017
ABPI briefing on the Falsified Medicines Directive (FMD) FEB 2017
Association of the British Pharmaceutical Industry (ABPI)
TGOs versus Pharmacopoeias: Do I have a choice?
TGOs versus Pharmacopoeias: Do I have a choice?
TGA Australia
Presentation: A spotlight on other reforms from the medicines and medical dev...
Presentation: A spotlight on other reforms from the medicines and medical dev...
TGA Australia
From Research to Public Service: What do scientists and engineers do at the TGA
From Research to Public Service: What do scientists and engineers do at the TGA
TGA Australia
Presentation: Online Clinical Trial Notification (CTN)
Presentation: Online Clinical Trial Notification (CTN)
TGA Australia
Presentation: What’s new in the 2019 RMP guidance update?
Presentation: What’s new in the 2019 RMP guidance update?
TGA Australia
2021_PV support by DADA
2021_PV support by DADA
Angela van der Salm
Road towards GVP VII Rev II - Explanatory note updates
Road towards GVP VII Rev II - Explanatory note updates
Dr. Rohith K Nair
The essential changes in the new pbrer format
The essential changes in the new pbrer format
Konstantin Kachulev, MScPharm
Presentation: Implementing TGO 101
Presentation: Implementing TGO 101
TGA Australia
Pharmacovigilance Programs of India PvPi
Pharmacovigilance Programs of India PvPi
SachinKumar2160
RMP_14th Annual Conference of Society of Pharmacovigilance and International ...
RMP_14th Annual Conference of Society of Pharmacovigilance and International ...
Dr Vineet Shastri
Presentation: CMA Advertising Seminar
Presentation: CMA Advertising Seminar
TGA Australia
Pharmacovigilance in the Middle East
Pharmacovigilance in the Middle East
Amjád Atrásh
Trainings from net zealous llc on new eu pharmacovigilance directive and regu...
Trainings from net zealous llc on new eu pharmacovigilance directive and regu...
NetZealous LLC
Aysun Karatas MedicReS World Congress 2015
Aysun Karatas MedicReS World Congress 2015
MedicReS
Más contenido relacionado
La actualidad más candente
Presentation: Prescription Medicines Reforms
Presentation: Prescription Medicines Reforms
TGA Australia
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
László Árvai
Periodic Safety Update Reports: Some commonly asked questions
Periodic Safety Update Reports: Some commonly asked questions
TGA Australia
ABPI briefing on the Falsified Medicines Directive (FMD) OCT 2016
ABPI briefing on the Falsified Medicines Directive (FMD) OCT 2016
Association of the British Pharmaceutical Industry (ABPI)
Presentation: The Australian and International landscape - keynote forum
Presentation: The Australian and International landscape - keynote forum
TGA Australia
Presentation: Spotlight on prescription medicine post-market reforms
Presentation: Spotlight on prescription medicine post-market reforms
TGA Australia
ABPI briefing on the Falsified Medicines Directive (FMD) FEB 2017
ABPI briefing on the Falsified Medicines Directive (FMD) FEB 2017
Association of the British Pharmaceutical Industry (ABPI)
TGOs versus Pharmacopoeias: Do I have a choice?
TGOs versus Pharmacopoeias: Do I have a choice?
TGA Australia
Presentation: A spotlight on other reforms from the medicines and medical dev...
Presentation: A spotlight on other reforms from the medicines and medical dev...
TGA Australia
From Research to Public Service: What do scientists and engineers do at the TGA
From Research to Public Service: What do scientists and engineers do at the TGA
TGA Australia
Presentation: Online Clinical Trial Notification (CTN)
Presentation: Online Clinical Trial Notification (CTN)
TGA Australia
Presentation: What’s new in the 2019 RMP guidance update?
Presentation: What’s new in the 2019 RMP guidance update?
TGA Australia
2021_PV support by DADA
2021_PV support by DADA
Angela van der Salm
Road towards GVP VII Rev II - Explanatory note updates
Road towards GVP VII Rev II - Explanatory note updates
Dr. Rohith K Nair
The essential changes in the new pbrer format
The essential changes in the new pbrer format
Konstantin Kachulev, MScPharm
Presentation: Implementing TGO 101
Presentation: Implementing TGO 101
TGA Australia
Pharmacovigilance Programs of India PvPi
Pharmacovigilance Programs of India PvPi
SachinKumar2160
RMP_14th Annual Conference of Society of Pharmacovigilance and International ...
RMP_14th Annual Conference of Society of Pharmacovigilance and International ...
Dr Vineet Shastri
Presentation: CMA Advertising Seminar
Presentation: CMA Advertising Seminar
TGA Australia
Pharmacovigilance in the Middle East
Pharmacovigilance in the Middle East
Amjád Atrásh
La actualidad más candente
(20)
Presentation: Prescription Medicines Reforms
Presentation: Prescription Medicines Reforms
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
Periodic Safety Update Reports: Some commonly asked questions
Periodic Safety Update Reports: Some commonly asked questions
ABPI briefing on the Falsified Medicines Directive (FMD) OCT 2016
ABPI briefing on the Falsified Medicines Directive (FMD) OCT 2016
Presentation: The Australian and International landscape - keynote forum
Presentation: The Australian and International landscape - keynote forum
Presentation: Spotlight on prescription medicine post-market reforms
Presentation: Spotlight on prescription medicine post-market reforms
ABPI briefing on the Falsified Medicines Directive (FMD) FEB 2017
ABPI briefing on the Falsified Medicines Directive (FMD) FEB 2017
TGOs versus Pharmacopoeias: Do I have a choice?
TGOs versus Pharmacopoeias: Do I have a choice?
Presentation: A spotlight on other reforms from the medicines and medical dev...
Presentation: A spotlight on other reforms from the medicines and medical dev...
From Research to Public Service: What do scientists and engineers do at the TGA
From Research to Public Service: What do scientists and engineers do at the TGA
Presentation: Online Clinical Trial Notification (CTN)
Presentation: Online Clinical Trial Notification (CTN)
Presentation: What’s new in the 2019 RMP guidance update?
Presentation: What’s new in the 2019 RMP guidance update?
2021_PV support by DADA
2021_PV support by DADA
Road towards GVP VII Rev II - Explanatory note updates
Road towards GVP VII Rev II - Explanatory note updates
The essential changes in the new pbrer format
The essential changes in the new pbrer format
Presentation: Implementing TGO 101
Presentation: Implementing TGO 101
Pharmacovigilance Programs of India PvPi
Pharmacovigilance Programs of India PvPi
RMP_14th Annual Conference of Society of Pharmacovigilance and International ...
RMP_14th Annual Conference of Society of Pharmacovigilance and International ...
Presentation: CMA Advertising Seminar
Presentation: CMA Advertising Seminar
Pharmacovigilance in the Middle East
Pharmacovigilance in the Middle East
Destacado
Trainings from net zealous llc on new eu pharmacovigilance directive and regu...
Trainings from net zealous llc on new eu pharmacovigilance directive and regu...
NetZealous LLC
Aysun Karatas MedicReS World Congress 2015
Aysun Karatas MedicReS World Congress 2015
MedicReS
Pharmacovigilance and product quality assessment
Pharmacovigilance and product quality assessment
pi
Pharmacovigilance - Processes & Challenges
Pharmacovigilance - Processes & Challenges
pi
Pharmacovigilance nrsmch
Pharmacovigilance nrsmch
Anindya Banerjee
Synopsis Of How To Write Psur
Synopsis Of How To Write Psur
Dr.S.Gunasakaran, MD
Guideline on good pharmacovigilance practices ( gvp)
Guideline on good pharmacovigilance practices ( gvp)
Nahla Amin
EU Pharmacovigilance legislation
EU Pharmacovigilance legislation
Arete-Zoe, LLC
Pharmacovigilance in USA and Europe_Katalyst HLS
Pharmacovigilance in USA and Europe_Katalyst HLS
Katalyst HLS
Destacado
(9)
Trainings from net zealous llc on new eu pharmacovigilance directive and regu...
Trainings from net zealous llc on new eu pharmacovigilance directive and regu...
Aysun Karatas MedicReS World Congress 2015
Aysun Karatas MedicReS World Congress 2015
Pharmacovigilance and product quality assessment
Pharmacovigilance and product quality assessment
Pharmacovigilance - Processes & Challenges
Pharmacovigilance - Processes & Challenges
Pharmacovigilance nrsmch
Pharmacovigilance nrsmch
Synopsis Of How To Write Psur
Synopsis Of How To Write Psur
Guideline on good pharmacovigilance practices ( gvp)
Guideline on good pharmacovigilance practices ( gvp)
EU Pharmacovigilance legislation
EU Pharmacovigilance legislation
Pharmacovigilance in USA and Europe_Katalyst HLS
Pharmacovigilance in USA and Europe_Katalyst HLS
Similar a Building on Drug Safety - the new EU guidelines May 2012
VOLUME 9A ppt.pptx
VOLUME 9A ppt.pptx
AartiVats5
Periodic safety update reports – gvp guidelines and changes
Periodic safety update reports – gvp guidelines and changes
Turacoz Healthcare Solutions
The New EU MDR and What You Need to Know
The New EU MDR and What You Need to Know
EMMAIntl
Rephine symposium 2018
Rephine symposium 2018
Alex Aves
2015_PV support by DADA
2015_PV support by DADA
Angela van der Salm
Pharmacovigilance programme of india what you need to know
Pharmacovigilance programme of india what you need to know
Himanshu Bhatnagar, MD
Pharmacovigilance Planning
Pharmacovigilance Planning
ClinosolIndia
ICH & It's Guidelines
ICH & It's Guidelines
Md Mostafijur Rahman
Marco Cavaleri: Post-approval benefit risk monitoring of vaccines: EMA perspe...
Marco Cavaleri: Post-approval benefit risk monitoring of vaccines: EMA perspe...
European Centre for Disease Prevention and Control
IDMP with PLG
IDMP with PLG
Alison Fautré
Presentation: The Australian Pharmacovigilance Inspection Program
Presentation: The Australian Pharmacovigilance Inspection Program
TGA Australia
Eu hot topics alliance presentation
Eu hot topics alliance presentation
Erik Vollebregt
Eu hot topics alliance presentation 3
Eu hot topics alliance presentation 3
Erik Vollebregt
Eu hot topics alliance presentation 2
Eu hot topics alliance presentation 2
Erik Vollebregt
TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?
TGA Australia
Building a link between ectd and xevmpd
Building a link between ectd and xevmpd
Qdossier B.V.
Chappuis Halder - EU Benchmark Regulation threepager - May 2016
Chappuis Halder - EU Benchmark Regulation threepager - May 2016
Nicolas Heguy
Regulatory Reporting in Pharmacovigilance: Compliance and Best Practices
Regulatory Reporting in Pharmacovigilance: Compliance and Best Practices
ClinosolIndia
ICH pharmacovigilance planning, an efficacy guideline
ICH pharmacovigilance planning, an efficacy guideline
bibilicavesela
Pharmaceutical inspection convention
Pharmaceutical inspection convention
RAGHAV DOGRA
Similar a Building on Drug Safety - the new EU guidelines May 2012
(20)
VOLUME 9A ppt.pptx
VOLUME 9A ppt.pptx
Periodic safety update reports – gvp guidelines and changes
Periodic safety update reports – gvp guidelines and changes
The New EU MDR and What You Need to Know
The New EU MDR and What You Need to Know
Rephine symposium 2018
Rephine symposium 2018
2015_PV support by DADA
2015_PV support by DADA
Pharmacovigilance programme of india what you need to know
Pharmacovigilance programme of india what you need to know
Pharmacovigilance Planning
Pharmacovigilance Planning
ICH & It's Guidelines
ICH & It's Guidelines
Marco Cavaleri: Post-approval benefit risk monitoring of vaccines: EMA perspe...
Marco Cavaleri: Post-approval benefit risk monitoring of vaccines: EMA perspe...
IDMP with PLG
IDMP with PLG
Presentation: The Australian Pharmacovigilance Inspection Program
Presentation: The Australian Pharmacovigilance Inspection Program
Eu hot topics alliance presentation
Eu hot topics alliance presentation
Eu hot topics alliance presentation 3
Eu hot topics alliance presentation 3
Eu hot topics alliance presentation 2
Eu hot topics alliance presentation 2
TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?
Building a link between ectd and xevmpd
Building a link between ectd and xevmpd
Chappuis Halder - EU Benchmark Regulation threepager - May 2016
Chappuis Halder - EU Benchmark Regulation threepager - May 2016
Regulatory Reporting in Pharmacovigilance: Compliance and Best Practices
Regulatory Reporting in Pharmacovigilance: Compliance and Best Practices
ICH pharmacovigilance planning, an efficacy guideline
ICH pharmacovigilance planning, an efficacy guideline
Pharmaceutical inspection convention
Pharmaceutical inspection convention
Más de Doctors.net.uk
M3 eumar16
M3 eumar16
Doctors.net.uk
What doctors think about NICE
What doctors think about NICE
Doctors.net.uk
Timringrosesept12
Timringrosesept12
Doctors.net.uk
Rtc med-directors event-2012-05-16
Rtc med-directors event-2012-05-16
Doctors.net.uk
Pharma times mobile[2]
Pharma times mobile[2]
Doctors.net.uk
Pharmacovigilance in real life may 12
Pharmacovigilance in real life may 12
Doctors.net.uk
Workshop
Workshop
Doctors.net.uk
Dr Hamzah Baig
Dr Hamzah Baig
Doctors.net.uk
Dr Nick Broughton
Dr Nick Broughton
Doctors.net.uk
NHS Reforms and the healthcare landscape
NHS Reforms and the healthcare landscape
Doctors.net.uk
Más de Doctors.net.uk
(10)
M3 eumar16
M3 eumar16
What doctors think about NICE
What doctors think about NICE
Timringrosesept12
Timringrosesept12
Rtc med-directors event-2012-05-16
Rtc med-directors event-2012-05-16
Pharma times mobile[2]
Pharma times mobile[2]
Pharmacovigilance in real life may 12
Pharmacovigilance in real life may 12
Workshop
Workshop
Dr Hamzah Baig
Dr Hamzah Baig
Dr Nick Broughton
Dr Nick Broughton
NHS Reforms and the healthcare landscape
NHS Reforms and the healthcare landscape
Último
HyperIgE syndrome: primary immune deficiency.pdf
HyperIgE syndrome: primary immune deficiency.pdf
Chulalongkorn Allergy and Clinical Immunology Research Group
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
Monika Kanwar
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
Sherrylee83
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
marcuskenyatta275
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
Cancer Institute NSW
Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptx
palsonia139
DR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in India
Nehamehta128467
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 ppt
desktoppc
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Ayman Seddik
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
DR SETH JOTHAM
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
Sergio Pinski
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
Dr. Rabia Inam Gandapore
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulation
MedicoseAcademics
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
Suresh Kumar K
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
marcuskenyatta275
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptx
claviclebrown44
5cladba raw material 5CL-ADB-A precursor raw
5cladba raw material 5CL-ADB-A precursor raw
Sherrylee83
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.
Anjali Parmar
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
NephroTube - Dr.Gawad
Evidence-based practiceEBP) in physiotherapy
Evidence-based practiceEBP) in physiotherapy
Nehaa Dubey
Último
(20)
HyperIgE syndrome: primary immune deficiency.pdf
HyperIgE syndrome: primary immune deficiency.pdf
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptx
DR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in India
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 ppt
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulation
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptx
5cladba raw material 5CL-ADB-A precursor raw
5cladba raw material 5CL-ADB-A precursor raw
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Evidence-based practiceEBP) in physiotherapy
Evidence-based practiceEBP) in physiotherapy
Building on Drug Safety - the new EU guidelines May 2012
1.
Safeguarding public health Building
on drug safety: How new EU regulations are changing pharmacovigilance Claire Tilstone May 2012 ©
2.
London 2012 European Medicines
Agency (EMA) and MHRA ushering in a new era in drug safety • Building on principles in volume 9A • Regulation (EU) No1235/2010 • Directive 2010/84/EU (to be transposed into UK Human Medicines Regulation 2012) • Underpinned by a series of Implementing Measures and Transitional Arrangements Key principles: 9. Proportionality; risk-based approach 10. Risks considered in the context of benefits 11. Considering outcomes and effectiveness of regulation Slide 2 ©
3.
Good pharmacovigilance practice New
guidelines for conduct of pharmacovigilance in EU are outlines in Good Pharmacovigilance Practice (GVP) modules Wave I topics recently subject to public consultation: • I. Pharmacovigilance systems and their quality systems • II. Pharmacovigilance system master file • V. Risk management systems • VI. Management and reporting of adverse reactions • VII. Periodic Safety Update Report • VIII. Post-authorisation safety studies • IX. Signal management Further waves due to be published in 2012 covering topics such as communications and audit Slide 3 ©
4.
Key areas • Audit
and inspection • Adverse drug reaction (ADR) reporting and signal management • Risk minimisation • Committees and referrals • Communications and transparency Slide 4 ©
5.
Audit and inspection Requirements
for information provided to Member States and EMA about pharmacovigilance system(s) of marketing authorisation holders (MAHs) change in several ways: • Summary information only on EU qualified person for pharmacovigilance (QPPV) and location of a pharmacovigilance system master file (PSMF) will be contained in marketing authorisations • Full descriptive information about pharmacovigilance systems will have to be contained in PSMF, available to Competent Authorities on request) • Detailed requirements for PSMF concern its availability, structure, content and maintenance • PSMF will encompass pharmacovigilance system and may relate to one or more products; content changes not automatically notifiable to Competent Authorities • Differs from current Detailed Description of the Pharmacovigilance system (DDPS), which will be phased out from July 2012–15 Slide 5 ©
6.
ADR reporting and
signal management • Patients included as valid reporters of ADRs • Definition of ADR extended to include harm from “noxious and unintended” reaction: ie, error, misuse, abuse, off-label • Centralised reporting to Eudravigilance (likely 2015) • EU-wide list of products subject to additional monitoring (to include biosimilars and biologicals); phasing out of UK Black Triangle Scheme • PSURs: cumulative benefit-risk evaluation of signals • Rationalisation via: modular structure; waivers; risk-based Slide 6 ©
7.
Risk minimisation • Focus:
forward-planning; dynamic; proportionate; transparent; auditable • Risk management plans required for all new marketing authorisations (MAs) from July 2012 (modular structure) • Post-authorisation safety/efficacy studies may be a new obligation (condition) on or after granting an MA Slide 7 ©
8.
Committees and referrals •
There will be a new EU committee: the Pharmacovigilance Risk Assessment Committee (PRAC) to advise current CHMP and CMDh committees • New oversight in relation to risk minimisation via assessment of PSURs, RMP, PASS • Role also in referrals; transitional arrangements will outline how legislation affects trigger date Slide 8 ©
9.
Communications and transparency •
Role of MAHs: timely and objective notifications • National web portals to host range of transparency documents: - SPCs and PILs - Summaries of Risk Management Plans - Public Assessment Reports (including conditions) - Products under additional monitoring - ADR reporting forms • EMA web portal expected to host further information relating to: - PASS abstracts, protocols and study reports - Committee details • There will be EU public hearings on drug safety Slide 9 ©
10.
Further information and
links • MHRA: http://www.mhra.gov.uk/Howweregulate/Medicines/Pharmacovigilancelegislation/index.htm Email: pv2012@mhra.gsi.gov.uk • EMA: - Regulation: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do? uri=OJ:L:2010:348:0001:0016:EN:PDF - Directive: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do? uri=OJ:L:2010:348:0074:0099:EN:PDF - Draft Implementing Measures: http://ec.europa.eu/enterprise/tbt/tbt_repository/EU29_EN_1_1.pdf - Transitional arrangements: http://www.ema.europa.eu/ema/index.jsp? curl=pages/news_and_events/news/2012/02/news_detail_001450.jsp&mid=WC0b01ac0580 04d5c1&jsenabled=true - GVP modules: http://www.ema.europa.eu/ema/index.jsp? curl=pages/news_and_events/news/2012/02/news_detail_001451.jsp&mid=WC0b01ac0580 04d5c1&jsenabled=true - Union Reference Date list on PSUR periodicity consultation: http://www.ema.europa.eu/ema/index.jsp? curl=pages/news_and_events/news/2012/03/news_detail_001479.jsp&mid=WC0b01ac0580 04d5c1]&jsenabled=true Email: p-pv-helpdesk@ema.europa.eu Slide 10 ©
Descargar ahora